(The Center Square) – Republican Louisiana U.S. Sen. Bill Cassidy and four colleagues have sent letters to three abortion drug manufacturing companies demanding the companies disclose more information about their compliance with the oversight and risk evaluation guidelines under the Food and Drug Administration.
Each company makes mifepristone, a drug used in a regimen to end an early pregnancy that has faced growing scrutiny as federal restrictions on its use have loosened. The companies include Danco Laboratories, GenBioPro., and Evita Solutions, the only three FDA approved manufacturers for the drug.
The letters accuse the manufacturers of secrecy and other questionable practices, calling on the companies to produce inspection documents, information regarding their supply chain and data on their revenue.
“This level of secrecy is unusual,” the letter to Evita said, adding that “most pharmaceutical companies are far more transparent, including disclosing where their drugs are manufactured, their leadership teams, and other basic information about their business.”
Since the FDA first approved the mifepristone REMS in 2011, the rules have changed significantly. The agency expanded approved use from seven weeks of pregnancy to 10 weeks in 2016, narrowed adverse-event reporting requirements, and later removed the in-person dispensing requirement. Even still, the letters worry that the companies are not meeting the requirements.
Each of the companies manufacture the drug, which is then given to a distributor who gives it to a pharmacy and is then finally given to the patient. The current rules specifically require the manufacturer to assess distributors’ performance and take steps if distributors are not complying. The letters worry that the three manufacturers are not.
For instance, the letter to GenBioPro questions whether the manufacturer is directing patients to providers that are violating the 10-week rule, saying, “It seems unlikely that GenBioPro is effectively enforcing compliance with the Mifepristone REMS Program when it appears to actively facilitate access to its drug outside of the window for which it is approved by FDA.”
The companies are requested to comply by April 8. As a legal matter, a committee request letter is not the same thing as a subpoena. The Senate HELP Committee’s own rules say subpoenas may issue only if the investigative activity is authorized by a majority vote of the committee.
Louisiana Attorney General Liz Murrill has spent months warning about the spread of mail-order abortion pills and has said she is preparing legal action against California, though no lawsuit has been filed.
Earlier in 2026, Murrill announced she had secured an indictment against a California doctor accused of sending abortion pills to Louisiana. After that, Gov. Jeff Landry asked California to extradite the doctor to Louisiana, but Gov. Gavin Newsom refused in a profanity-laced reply.
The Trump administration has continued defending the FDA’s current mifepristone framework, including the loosened access rules challenged by Texas, Missouri and Idaho, as reported by Reuters.
